A Palladium Iodide-Catalyzed Cyclocarbonylation Approach to Thiadiazafluorenones

Lucia Veltri,*^{,†} Veronica Paladino,[†] Pierluigi Plastina,[‡] and Bartolo Gabriele^{*,†}

[†]Laboratory of Industrial and Synthetic Organic Chemistry (LISOC), Department of Chemistry and Chemical Technologies, University of Calabria, Via Pietro Bucci 12/C, 87036 Arcavacata di Rende (CS), Italy

[‡]Department of Chemistry and Chemical Technologies, University of Calabria, Via Pietro Bucci 14/C, 87036 Arcavacata di Rende (CS), Italy

Supporting Information

ABSTRACT: The first example of an additive cyclocarbonylation process leading to 1-thia-4*a*,9-diazafluoren-4-ones is reported. This process is based on the reaction of readily available 2-(propynylthio)benzimidazoles with carbon monoxide carried out in EtOH at 100 °C under a 5/2 mixture of CO–CO₂ at 70 atm in the presence of the PdI₂/KI catalytic system. Experimental evidence suggests a mechanistic pathway involving *N*-palladation of the substrate followed by CO insertion, triple bond insertion, protonolysis, and isomerization.

1-Thiadiazafluoren-4-ones are an important class of polyheterocyclic compounds known to possess important pharmacological activities.^{1,2} In particular, some 1-thiazafluorenone derivatives have shown a positive inotropic effect and strong cardiotonic activity,² while other derivatives are known to be antihyper secretion agents.² They are usually prepared by intramolecular amidation of 3-(1*H*-benzo[*d*]imidazol-2-ylthio)propanoic acid and its derivatives.³ Clearly, the possibility to synthesize them by a direct carbonylation procedure involving the use of the simplest and most available C-1 unit (carbon monoxide) would represent a very attractive alternative synthetic approach. Currently, cyclocarbonylation constitutes a method of primary importance for the construction of a ring with direct incorporation of the carbonyl group into the cycle starting from CO.⁴ In particular, palladium-catalyzed cyclocarbonylation reactions of unsaturated substrates bearing a nucleophilic group in a suitable position for cyclization have been proven to be particularly significant for the synthesis of carbonylated heterocycles, with many important examples being reported in the recent literature.⁴⁻⁶

Herein, we report a novel cyclocarbonylation route to 1-thia-4a,9-diazafluoren-4-one **2** starting from readily available 2-(prop-2-ynylthio)-1*H*-benzo[*d*]imidazoles **1**.⁷ The process, catalyzed by a simple catalytic system consisting of PdI₂ in conjunction with KI and promoted by an excess of carbon dioxide, corresponds to a 6-*exo*-dig carbonylative cyclization in which the nitrogen of the imidazole ring of **1** acts as nucleophile, followed by in situ isomerization of the ensuing double bond from the exocyclic to the endocyclic position (Scheme 1).

2-(Prop-2-ynylthio)-1H-benzo[d]imidazole 1a was used as model substrate for optimizing the reaction conditions that



Scheme 1. PdI_2 -Catalyzed Cyclocarbonylation of 2-(Prop-2ynylthio)-1*H*-benzo[*d*]imidazoles 1 Followed by Double Bond Isomerization Leading to 1-Thia-4*a*,9-diazafluoren-4one 2



would lead to the polyheterocyclic derivatives 2. This substrate was initially allowed to react with carbon monoxide (30 atm) at 100 °C in MeOH as the solvent (1a concentration = 0.1 mmol per milliliter of solvent) in the presence of PdI_2 (2 mol %) and KI (1 equiv). After 3 h, substrate conversion was quantitative, and analysis of the reaction mixture evidenced the formation of the desired product, 3-methyl-1-thia-4a,9-diazafluoren-4-one 2a, in 37% yield, together with heavy unidentified compounds (chromatographically immobile materials) (Table 1, entry 1).⁸ Although the yield of 2a was modest, this initial result confirmed the possibility to realize the direct synthesis of a thiadiazafluorenone by a PdI2-catalyzed cyclocarbonylation route. With the aim of improving the selectivity of 2a, we then changed the reaction parameters, such as the nature of the catalyst, substrate concentration, reaction temperature, and solvent (Table 1). The use of PdCl₂/KCl instead of PdI₂/KI led to less-satisfactory results (Table 1, entry 2), while practically the same yield of 2a was obtained by replacing KI with

Received: May 3, 2016 **Published:** June 16, 2016 Table 1. Carbonylation Reaction of 2-(Prop-2-ynylthio)-1*H*benzo[*d*]imidazole 1a under Different Conditions^{*a*}



^{*a*}Unless otherwise noted, all reactions were carried out under CO at 30 atm (25 °C) for 3 h with a substrate concentration of 0.1 mmol of **1a** per milliliter of solvent in the presence of 2 mol % of the palladium catalyst. Unless otherwise noted, substrate conversion was quantitative. ^{*b*}Isolated yield based on starting amount of **1a**. ^{*c*}Substrate conversion was 76% by isolation of unreacted substrate. ^{*d*}Substrate conversion was 68% by isolation of unreacted substrate. ^{*c*}The reaction was carried out using 2-(prop-2-ynylthio)-1*H*-benzo[*d*]imidazolium bromide **1a**' as the substrate instead of **1a**. ^{*f*}The reaction was carried out with a substrate concentration of 0.2 mmol per milliliter of solvent. ^{*g*}The reaction was carried out under a 3/2 mixture of CO–CO₂ at 50 atm (25 °C).

diethylammonium iodide (Table 1, entry 3). On the other hand, lower yields of 2a were observed using $PdCl_2(PPh_3)_2$ (Table 1, entry 4) or a Pd(0) complex such as $Pd(dba)_2$ (Table 1, entry 5). A lower yield was also observed with 10 mol % KI rather than 1 equiv (Table 1, entry 6), working at 80 °C rather than 100 °C (Table 1, entry 7), and using 2-(prop-2-ynylthio)-1*H*-benzo[d]imidazolium bromide 1a' as the substrate instead of 1a (Table 1, entry 8). Selectivity toward 2a was instead improved when working under more concentrated conditions (0.2 rather than 0.1 mmol of 1a per milliliter of MeOH Table 1, entry 9) or under higher CO pressure (50 atm, Table 1, entry 10). Interestingly, the use of a $CO-CO_2$ mixture (30/20 atm) also tended to augment the product yield (Table 1, entry 11). The nature of the solvent was also very important for product selectivity. In particular, the process worked well not only in MeOH but also in another protic solvent such as EtOH (Table 1, entry 12), while less-satisfactory results were obtained in aprotic solvents such as dioxane, DME, MeCN, or DMA (Table 1, entries 13-16).

Under the final optimized conditions (2 mol % PdI_2 and 1 equiv of KI at 100 °C for 3 h in EtOH (1a concentration = 0.2

mmol per milliliter of solvent) under a CO/CO_2 mixture (50/20 atm) at 70 atm), the desired thiadiazafluorenone was isolated in 65% yield (Table 2, entry 1). The process was then extended to differently substituted substrates **1b**-**f**.

As can be seen from the results shown in Table 2, entries 2– 6, the process was quite general, as it worked nicely with substrates bearing electron-withdrawing groups as well as electron-donating groups on the aromatic ring. 5-Fluoro-2-(prop-2-ynylthio)-1*H*-benzo[*d*]imidazole 1f was less reactive than the other substrates tested; thus, its carbonylation was carried out for 15 h with a 5 mol % PdI₂ (Table 2, entry 6). Quite predictably, on the basis of the similar reactivity of the two nitrogens of the benzimidazole ring due to conjugation, a mixture of regioisomers was formed, starting from monosubstituted substrates 1e and 1f (Table 2, entries 5 and 6, respectively).

Based on our experiences with PdI₂/KI-catalyzed carbonylation reactions^{5a,c,9} and the experimental results obtained in this work, we propose the mechanism shown in Scheme 2 for rationalizing the formation of thiadiazafluorenones 2 from (propynylthio)benzimidazoles 1 under our conditions (anionic iodide ligands are omitted for clarity). The fact that practically no reaction occurs with a classical Pd(0) catalyst such as $Pd(dba)_2$ (Table 1, entry 4) seems to rule out a Pd(0)mediated mechanism initiated by oxidative addition of the N-H group of the substrate to a Pd(0) species formed in situ under the reaction conditions. Accordingly, a Pd(II)-catalyzed process initiated by N-palladation of 1 with PdI₂ to give complex I and HI appears much more likely (Scheme 2). Carbon monoxide insertion into the N-Pd bond of I would lead to carbamoylpalladium intermediate II, from which the final product would be obtained by triple bond insertion to give III, protonolysis by HI (leading to intermediate IV), and isomerization. This mechanistic hypothesis is also in agreement with the higher activity displayed by the PdI₂/KI system with respect to PdCl₂/KCl because, on one hand, iodide is a better leaving group in the N-palladation step and, on the other hand, HI is a stronger acid in the protonolysis step.¹⁰ The importance of an effective protonolysis step with regeneration of the Pd(II) catalyst is further demonstrated by the experimental observation that the process works much better in protic solvents, where HI dissociation is more favored, rather than in aprotic ones. Finally, although the favorable effect exerted by CO₂ is difficult to interpret, the excess CO₂ may also favor the protonolysis step by slightly augmenting the acidity of the reaction medium. It may also act as a ligand to Pd(II),¹¹ suitably stabilizing the key organometallic intermediates leading to 2.

In conclusion, we developed a novel cyclocarbonylative method for the direct synthesis of thiadiazafluorenones **2** starting from readily available (propynylthio)benzimidazoles **1**. The process, catalyzed by the simple catalytic system PdI_2/KI , occurs in EtOH under relatively mild conditions (100 °C, under a 5/2 mixture of CO–CO₂ at 70 atm) and takes place through an ordered sequence of steps involving *N*-palladation, CO insertion, triple bond insertion, protonolysis, and isomerization. To the best of our knowledge, this is the first example of synthesis of polyheterocycles **2** by a direct additive carbonylation approach.

EXPERIMENTAL SECTION

General Experimental Methods. Solvents and chemicals were reagent grade and used without further purification. All reactions were

Table 2. Synthesis of 1-Thia-4*a*,9-diazafluoren-4-one 2 by PdI_2 -Catalyzed Cyclocarbonylation of 2-(Prop-2-ynylthio)-1*H*-benzo[*d*]imidazoles 1^{*a*}



^{*a*}Unless otherwise noted, all reactions were carried out at 100 °C for 3 h in EtOH as the solvent (0.2 mmol of 1 per milliliter of EtOH) under a 5/2 mixture of CO–CO₂ at 70 atm (25 °C) in the presence of PdI₂ (2 mol %) in conjunction with KI (1 equiv). Substrate conversion was quantitative in all cases. The formation of heavy products (chromatographically immobile materials) accounted for the difference between product yield and substrate conversion. ^{*b*}Isolated yield based on starting amount of 1. ^{*c*}Mixture of regioisomers (~1.2/1, by GLC). ^{*d*}Mixture of regioisomers (~1.4/1, by ¹H NMR). ^{*e*}The reaction was carried out with 5 mol % PdI₂ for 15 h.

analyzed by TLC on silica gel 60 F254 and by GLC using capillary columns with polymethylsilicone +5% phenylsilicone as the stationary phase. Column chromatography was performed on silica gel 60 (70–230 mesh) or alumina gel 90 (70–230 mesh). Evaporation refers to the removal of solvent under reduced pressure. Melting points are uncorrected. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C on a 300 or 500 MHz spectrometers in CDCl₃, DMSO-*d*₆, or CD₃OD solutions with Me₄Si as the internal standard. ¹⁹F NMR spectra were recorded at 25 °C on a 500 MHz spectrometer in CDCl₃ solutions at 471 MHz with CF₂Br₂ or CFCl₃ as the internal standard. Chemical shifts (δ) and coupling constants (*J*) are given in ppm and Hz, respectively. IR spectra were taken with an FT-IR spectrometer. Mass spectra were obtained using a GC-MS apparatus at 70 eV ionization voltage and by electrospray ionization using an ESI-MS spectrometer.

The LC-MS was operated in the positive ion mode. The experimental conditions were as follows: ion spray voltage 4000 V; curtain gas 35 psi; temperature 25 $^{\circ}$ C; ion source gas 15 psi; declustering and focusing potentials 50 and 400 V, respectively. Microanalyses were carried out in our analytical laboratory.

Preparation of Substrate Precursors. Starting materials 1,3dihydrobenzimidazole-2-thiones were commercially available except for 5,6-dimethoxy-1,3-dihydrobenzimidazole-2-thione and 5-fluoro-1,3-dihydrobenzimidazole-2-thione, which were prepared according to the following procedure:¹² to a three-necked flask were introduced, under nitrogen, 4-fluorobenzene-1,2-diamine (2.0 g, 16.0 mmol) or 1,2-diamino-4,5-dimethoxybenzene¹³ (2.7 g, 16.0 mmol), carbon disulfide (2.4 g, 32.0 mmol), and a solution of KOH (1.8 g, 32 mmol) in anhydrous EtOH (26 mL). The mixture was refluxed under Scheme 2. Proposed Mechanistic Pathway for the PdI₂-Catalyzed Cyclocarbonylation of 2-(Prop-2-ynylthio)-1*H*benzo[*d*]imidazoles 1 Leading to 1-Thia-4*a*,9-diazafluoren-4-one 2



stirring for 4 h. After being cooled, glacial acetic acid (30 mL) was added to the mixture. The solvent was evaporated, and to the solid residue was added aq NaOH (2.5 wt %, 200 mL) containing a few drops of NaHSO₃. The mixture was refluxed until dissolution of the solid was observed, and after being cooled to 0 °C, the pH of the solution was adjusted to neutral by addition of concd HCl. To the resulting mixture was added AcOEt (100 mL); the phases were separated, and the aqueous phase was extracted with AcOEt (3 × 50 mL). The collected organic layers were dried over Na₂SO₄. After filtration and evaporation of the solvent, the product was purified by column chromatography on silica gel using 6/4 hexane AcOEt for 5-fluoro-1,3-dihydrobenzimidazole-2-thione.

5-Fluoro-1,3-dihydrobenzimidazole-2-thione. Yield: 2.2 g starting from 2 g of 4-fluorobenzene-1,2-diamine (80%). Yellow solid, mp: 227–229 °C; IR (KBr): ν 1630 (m), 1503 (s), 1471 (m), 1344 (s), 1252 (m), 1194 (m), 1145 (s), 985 (m), 837 (s), 703 (s), 658 (s) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ 7.20–7.11 (m, 1 H), 7.00–6.86 (m, 2 H); ¹³C NMR (75 MHz, CD₃OD): δ 170.9, 161.1 (d, *J* = 239), 134.4 (d, *J* = 13), 130.3, 111.6 (d, *J* = 10), 111.1 (d, *J* = 25), 98.3 (d, *J* = 29); ¹⁹F NMR (471 MHz, CD₃OD): δ –119.9 (s, 1 F); MS (ESI⁺, direct infusion): *m*/*z* 169 [(M + H)⁺]; Anal. calcd for C₇H₅FN₂S (168.19): C, 49.99; H, 3.00; F, 11.30; N, 16.66; S, 19.06; found C, 49.97; H, 3.02; F, 11.28; N, 16.61; S, 19.12.

5,6-Dimethoxy-1,3-dihydrobenzimidazole-2-thione. Yield: 2.0 g starting from 2.69 g of 1,2-diamino-4,5-dimethoxybenzene (60%). Yellow solid, mp: 289–290 °C, lit.^{12b} 289–290 °C; IR (KBr): ν 2360 (m), 1638 (m), 1510 (s), 1472 (m), 1460 (m), 1350 (s), 1249 (m), 1212 (m), 1186 (m), 1150 (m), 1014 (m), 901 (m), 829 (m), 729 (m) cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.31 (s, br, 2 H), 6.75 (s, 2 H), 3.76 (s, 6 H); ¹³C NMR (75 MHz, DMSO- *d*₆): δ 166.1, 145.9, 125.4, 94.5, 56.0; MS (ESI⁺, direct infusion): *m*/*z* 211 [(M + H)⁺]; Anal. calcd for C₉H₁₀N₂O₂S (210.25): C, 51.41; H, 4.79; N, 13.32; S, 15.25; found C, 51.60; H, 4.81; N, 13.29; S, 15.22.

Preparation of 2-(Prop-2-ynylthio)-1H-benzo[d]imidazoles To a solution of the 1,3-dihydrobenzimidazole-2-thione derivative (16.7 mmol) [1,3-dihydrobenzimidazole-2-thione: 2.50 g; 5,6dimethyl-1,3-dihydrobenzimidazole-2-thione: 2.97 g; 5,6-dichloro-1,3dihydrobenzimidazole-2-thione: 3.65 g; 5,6-dimethoxy-1,3-dihydrobenzimidazole-2-thione: 3.51 g; 5-methoxy-1,3-dihydrobenzimidazole-2-thione: 3.00 g; 5-fluoro-1,3-dihydrobenzimidazole-2-thione: 2.81 g] in anhydrous acetone (100 mL) was added, under nitrogen, K₂CO₃ (2.3 g, 16.7 mmol) followed by propargyl bromide (2.96 g, corresponding to 2.8 mL of a 80 wt % solution in toluene, 25.1 mmol). The mixture was stirred at room temperature for 20 h. After evaporation of the solvent, dichloromethane (30 mL) and water (30 mL) were sequentially added, and the phases were separated. The aqueous phase was extracted again with dichloromethane (20 mL), and finally the collected organic phases were dried over Na2SO4. After filtration and evaporation of the solvent, products 1a-f were purified by column chromatography on silica gel using as eluent 9/1 hexaneAcOEt for 1a-c and 1e and 7/3 hexane-AcOEt for 1d and 1f. 2-(Prop-2-ynylthio)-1*H*-benzo[*d*]imidazolium bromide 1a' was prepared as we already reported.^{12b}

2-(*Prop-2-ynylthio*)-1*H-benzo[d]imidazole* (1*a*). Yield: 2.51 g starting from 2.50 g of 1,3-dihydrobenzimidazole-2-thione (80%). Colorless solid, mp: 165–167 °C, lit.¹⁵: 164–165 °C and 165–167;^{12b} IR (KBr) ν 3048 (m), 2958 (m), 2888 (m), 2106 (vw), 1506 (w), 1444 (m), 1405 (s), 1351 (m), 1267 (m), 1227 (m), 1012 (m), 977 (m), 745 (s), 657 (m)cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.7 (s, br, 1 H), 7.56–7.42 (m, 2 H), 7.21–7.10 (m, 2 H), 4.16 (d, *J* = 2.6, 2 H), 3.22 (t, *J* = 2.6, 1 H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 148.3, 121.5, 114.3 (br), 80.0, 73.9, 19.7; MS (ESI⁺, direct infusion): *m/z* 189 [(M + H)⁺]; Anal. calcd for C₁₀H₈N₂S (188.25): C, 63.80; H, 4.28; N, 14.88; S, 17.03; found C, 63.89; H, 4.30; N, 14.85; S, 16.96.

5,6-Dimethyl-2-(prop-2-ynylthio)-1H-benzo[d]imidazole (1b). Yield: 3.25 g starting from 2.97 g of 5,6-dimethyl-1,3-dihydrobenzimidazole-2-thione (90%). Colorless solid, mp: 163–164 °C; IR (KBr) ν 3051 (m), 2920 (m), 2122 (vw), 1451 (s), 1415 (m), 1389 (s), 1299 (w), 1234 (w), 974 (m), 854 (m) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ 7.24 (s, 2 H), 4.92 (s, br, 1 H), 3.99–3.93 (m, 2 H), 2.65–2.57 (m, 1 H), 2.32 (s, 6 H); ¹³C NMR (75 MHz, CD₃OD): δ 148.5, 139.2, 132.8, 115.4, 79.8, 73.2, 22.3, 20.2; MS (ESI⁺, direct infusion): m/z 217 [(M + H)⁺]; Anal. calcd for C₁₂H₁₂N₂S (216.30): C, 66.63; H, 5.59; N, 12.95; S, 14.82; found C, 66.29; H, 5.61; N, 12.90; S, 15.20.

5,6-Dichloro-2-(prop-2-ynylthio)-1H-benzo[d]imidazole (1c). Yield: 3.21 g starting from 3.65 g of 5,6-dichloro-1,3-dihydrobenzimidazole-2-thione (75%). Colorless solid, mp: 185–188 °C; IR (KBr) ν 3270 (m), 2923 (m), 2122 (w), 1492 (w), 1402 (m), 1332 (m), 1260 (m), 1095 (m), 967 (m), 866 (m), 660 (s) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ 7.60 (s, 2 H), 4.92 (s, br, 1 H), 4.07 (d, *J* = 2.6, 2 H), 2.68 (t, *J* = 2.6, 1 H); ¹³C NMR (75 MHz, CD₃OD): δ 153.5, 140.3, 127.4, 116.5, 79.2, 73.5, 21.6; MS (ESi⁺, direct infusion): *m*/*z* 257 [(M + H)⁺]; Anal. calcd for C₁₀H₆Cl₂N₂S (257.139): C, 46.71; H, 2.35; Cl, 27.57; N, 10.89; S, 12.47; found C, 46.79; H, 2.33; Cl, 27.61; N, 10.86; S, 12.41.

5,6-Dimethoxy-2-(prop-2-ynylthio)-1H-benzo[d]imidazole (1d). Yield: 3.43 g starting from 3.51 g of 5,6-dimethoxy-1,3-dihydrobenzimidazole-2-thione (83%). Yellow solid, mp: 95–97 °C; IR (KBr) ν 3287 (m), 2116 (w), 1665 (m), 1632 (m), 1597 (m), 1511 (m), 1497 (m), 1453 (m), 1368 (m), 1339 (m), 1243 (m), 1216 (m), 1147 (m), 1012 (m), 989 (m), 857 (m), 734 (s) cm-¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.45 (s, br, 1 H), 7.03 (s, 2 H), 4.06 (d, *J* = 1.9, 2 H), 3.77 (s, 6 H), 3.22–3.16 (m, 1 H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 146.2, 144.9, 133.5, (br), 97.2 (br), 80.2, 73.9, 55.9, 20.5; MS (ESI⁺, direct infusion): *m*/*z* 249 [(M + H)⁺]; Anal. calcd for C₁₂H ₁₂N₂O₂S (248.30): C, 58.05; H, 4.87; N, 11.28; S, 12.91; found C, 57.91; H, 4.89; N, 11.26; S, 12.88.

5-Methoxy-2-(prop-2-ynylthio)-1H-benzo[d]imidazole (1e). Yield: 2.20 g starting from 3.00 g of 5-methoxy-1,3-dihydrobenzimidazole-2thione (60%). Colorless solid, mp: 140–142 °C; IR (KBr) ν 3262 (m), 2122 (vw), 1622 (m), 1456 (m), 1396 (s), 1342 (m), 1301 (m), 1272 (w), 1227 (m), 1158 (m), 1113 (w), 981 (m), 815 (m) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆): δ 12.6 (s, br, 1 H), 7.50–7.34 (m, 1 H), 7.17–6.93 (m, 1 H), 6.81 (dd, *J* = 8.6, 2.3, 1 H), 4.15 (d, *J* = 2.5, 2 H), 3.79 (s, 3 H), 3.22 (t, *J* = 2.5, 1 H); ¹³C NMR (75 MHz, DMSO-d₆): δ 155.4, 147.0, 137.1, 117.9, 110.7, 100.2, 94.5, 80.1, 73.9, 55.4, 20.0; MS (ESI⁺, direct infusion): *m*/*z* 219 [(M + H)⁺]; Anal. calcd for C₁₁H₁₀N₂OS (218.27): C, 60.53; H, 4.62; N, 12.83; S, 14.69; found C, 60.32; H, 4.60; N, 12.88; S, 14.72.

5-Fluoro-2-(prop-2-ynylthio)-1H-benzo[d]imidazole (1f). Yield: 2.10 g starting from 2.81 g of 5-fluoro-1,3-dihydrobenzimidazole-2thione (61%). Yellow solid, mp: 132–134 °C; IR (KBr) ν 3303 (m), 1633 (m), 1498 (s), 1461 (m), 1427 (m), 1362 (m), 1274 (m), 1242 (m), 1159 (m), 997 (m), 860 (m), 677 (m) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ 7.44 (dd, *J* = 8.8, 4.7, 1 H), 7.20 (dd, *J* = 9.1, 2.3, 1 H), 7.06–6.92 (m, 1 H), 4.06–4.01 (m, 2 H), 2.69–2.63 (m, 1 H); ¹³C NMR (75 MHz, CD₃OD): δ 161.1 (d, *J* = 238), 151.5, 141.1 (br), 137.4 (br), 116.0 (br), 111.5 (d, *J* = 26), 101.4 (d, *J* = 26), 79.8, 73.5, 73.4, 22.0; ¹⁹F NMR (471 MHz, CD₃OD): δ –113.5 (s); MS (ESI⁺,

The Journal of Organic Chemistry

direct infusion): m/z 207 [(M + H)⁺]; Anal. calcd for C₁₀H₇FN₂S (206.24): C, 58.24; H, 3.42; F, 9.21; N, 13.58; S, 15.55; found C, 58.29; H, 3.40; F, 9.18; N, 13.61; S, 15.52.

General Procedure for the Synthesis of Thiadiazafluorenones 2a–f (Table 2). A 250 mL stainless steel autoclave was charged in the presence of air with PdI₂ (5.8 mg, 1.61×10^{-2} mmol for 1a–e and 14.6 mg, 4.05×10^{-2} mmol for 1f), KI (134.0 mg, 0.81 mmol), anhydrous EtOH (4.0 mL), and 2-(prop-2-ynylthio)-1Hbenzo[d]imidazole (0.81 mmol) (1a: 153 mg; 1b: 175 mg; 1c: 208 mg; 1d: 201 mg; 1e: 177 mg; 1f: 167 mg). The autoclave was purged at room temperature several times with CO₂ under stirring (5 atm) and eventually pressurized with CO₂ (20 atm) and CO (up to 70 atm). After being stirred at 100 °C for 3 h (for 1a–e) or 15 h (for 1f), the autoclave was cooled, degassed, and opened. After evaporation of the solvent, products 2 were purified by column chromatography on alumina using 9/1 hexane-AcOEt (2b and 2c) or 8/2 hexane-AcOEt (2a, 2e, 2d, and 2f) as the eluent.

3-Methyl-1-thia-4a,9-diazafluoren-4-one (2a). Yield: 114 mg, starting from 153 mg of 1a (65%) (Table 2, entry 1). Colorless solid, mp: 170–172 °C; IR (KBr): ν 1680 (s), 1639 (m), 1618 (m), 1472 (m), 1401 (m), 1360 (m), 1310 (m), 1200 (w), 771 (m) cm⁻¹; ¹H NMR (300 MHz,CDCl₃): δ 8.54 (d, J = 7.8, 1 H), 7.76 (d, J = 7.7, 1 H), 7.54–7.36 (m, 2 H), 6.56–6.51 (m, 1 H), 2.48 (d, J = 0.9, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 159.6, 148.8, 146.7, 142.5, 131.2, 125.8, 124.2, 118.6, 116.1, 115.6, 22.8; GC-MS: *m*/*z* 216 (M⁺, 100), 188 (29), 175 (4), 150 (33), 143 (6), 129 (4), 122 (5), 108 (4), 90 (9); Anal. calcd for C₁₁H₈N₂OS (216.26): C, 61.09; H, 3.73; N 12.95; S, 14.83; found C, 61.35; H, 3.71; N 12.91; S, 14.89.

3,6,7-Trimethyl-1-thia-4a,9-diazafluoren-4-one (**2b**). Yield: 142 mg, starting from 175 mg of **1b** (72%) (Table 2, entry 2). Colorless solid, mp: 115–121 °C; IR (KBr): ν 1677 (s), 1377 (m), 1347 (m), 1315 (m), 1286 (m), 1184 (m), 1094 (w), 846 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.24 (s, 1 H), 7.45 (s, 1 H), 6.48–6.43, (m, 1 H), 2.44 (d, *J* = 1.1, 3 H), 2.39 (s, 3 H), 2.38 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 159.6, 148.2, 145.6, 141.6, 134.9, 133.5, 130.0, 119.0, 116.1, 115.8, 22.5, 20.2; GC-MS: *m*/*z* 244 (M⁺, 100), 229 (20), 216 (16), 201 (7), 178 (23), 163 (10), 157 (3), 122 (7), 91 (7), 67 (10); Anal. calcd for C₁₃H₁₂N₂OS (244.31): C, 63.91; H, 4.95; N 11.47; S, 13.12; found C, 63.80; H, 4.96; N 11.49; S, 13.09.

6,7-Dichloro-3-methyl-1-thia-4a,9-diazafluoren-4-one (2c). Yield: 164 mg, starting from 208 mg of 1c (71%) (Table 2, entry 3). Yellow solid, mp: 153–155 °C; IR (KBr): ν 1692 (s), 1467 (w), 1375 (m), 1340 (m), 1297 (m), 1190 (m), 1095 (m), 842 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.64 (s, 1 H), 7.82 (s, 1 H), 6.56 (q, J = 1.2, 1 H), 2.52 (d, J = 1.2, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 153.5, 140.3, 127.4, 116.5, 79.2, 73.5, 21.6; GC-MS: m/z 286 [(M + 2)⁺, 69], 284 (M⁺, 100), 258 (23), 256 (33), 220 (18), 218 (25), 199 (3), 181 (8), 158 (4), 142 (4), 100 (4), 88 (6), 67 (61); Anal. calcd for C₁₁H₆Cl₂N₂OS (285.15): C, 46.33; H, 2.12; Cl, 24.87; N 9.82; S, 11.24; found C, 46.21; H, 2.14; N 9.86; S, 11.27.

6,7-Dimethoxy-3-methyl-1-thia-4a,9-diazafluoren-4-one (2d). Yield: 150 mg, starting from 201 mg of 1d (67%) (Table 2, entry 4). Yellow solid, mp: 187–188 °C; IR (KBr): ν 1678 (s), 1465 (s), 1436 (s), 1340 (m), 1307 (m), 1193 (m), 1153 (m), 1016 (m), 862 (m), 830 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.02 (s, 1 H), 7.18 (s, 1 H), 6.48 (s, 1 H), 3.99 (s, 3 H), 3.96 (s, 3 H), 2.47 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 159.7, 149.6, 148.4, 144.2, 137.1, 132.2, 125.4, 115.5, 101.7, 100.0, 56.9, 56.6, 22.5; GC-MS: *m*/*z* 276 (M⁺, 100), 261 (28), 233 (6), 207 (11), 193 (5), 167 (5), 135 (5), 73 (6); Anal. calcd for C₁₃H₁₂N₂O₃S (276.31): C, 56.51; H, 4.38; N 10.14; S, 11.60; found C, 56.66; H, 4.36; N 10.17; S, 11.64.

Mixture of 6-Methoxy-3-methyl-1-thia-4a,9-diazafluoren-4-one and 7-Methoxy-3-methyl-1-thia-4a,9-diazafluoren-4-one (1.2/1 Mixture of Isomers A/B, by GLC) (**2e**). Yield: 148 mg, starting from 177 mg of **1e** (74%) (Table 2, entry 5). Yellow solid, mp: 125–130 °C; IR (KBr): ν 1689 (s), 1594 (w), 1478 (s), 1432 (m), 1366 (m), 1303 (m), 1277 (m), 1200 (m), 1155 (m), 1023 (m), 839 (m) cm⁻¹; ¹H NMR (300 MHz,CDCl₃): δ 8.37 (d, J = 9.0, A), 8.05 (d, J = 2.5, B), 7.61 (d, J = 8.8, B), 7.19 (d, J = 2.4, 1 H, A), 7.07 (dd, J = 8.8, 2.5, 1 H, B), 7.01 (dd, J = 9.0, 2.4, A), 6.51 (q, J = 1.1, 1 H, B), 6.48 (q, J = 1.1, 1 H, A), 3.91 (s, 3 H, B), 3.88 (s, 3 H, A), 2.48 (d, J = 1.2, 3 H, A), 2.47 (d, J = 1.1, 3 H, B) (Note: The A/B isomer assignments are based on ¹H NMR peak integration data: A refers to the major isomer and B refers to the minor isomer); ¹³C NMR (75 MHz, CDCl₃): δ 159.5, 158.79, 158.75, 157.5, 149.1, 148.5, 147.1, 144.9, 135.3, 131.7, 130.9, 128.8, 125.0, 118.5, 116.7, 115.7, 115.4, 114.1, 100.3, 99.5, 56.0, 55.8, 29.7, 22.8; GC-MS [A (major isomer)]: m/z 246 (M⁺, 100), 231 (42), 218 (7), 203 (14), 180 (21), 165 (29), 152 (4), 137 (4), 67 (36); GC-MS [B (minor isomer)]: m/z 246 (M⁺, 100), 231 (41), 218 (9), 203 (10), 180 (15), 165 (27), 152 (4), 137 (6), 123 (3), 89 (4), 67 (34); Anal. calcd for C₁₂H₁₀N₂O₂S (246.28): C, 58.52; H, 4.09; N 11.37; S, 13.02; found C, 58.37; H, 4.07; N 11.39; S, 13.05.

Mixture of 6-Fluoro-3-methyl-1-thia-4a,9-diazafluoren-4-one and 7-Fluoro-3-methyl-1-thia-4a,9-diazafluoren-4-one (1.4:1 mixture of isomers A:B, by ¹H NMR) (2f). Yield: 129 mg, starting from 167 mg of 1f (68%) (Table 2, entry 6). Colorless solid, mp: 125-128 °C; IR (KBr): v 1679 (s), 1466 (s), 1429 (s), 1355 (m), 1305 (m), 1135 (m), 958 (m), 862 (m), 813 (m) cm⁻¹; ¹H NMR (300 MHz, $CDCl_3$: δ 8.47 (dd, J = 9.0, 5.0, 1 H, A), 8.24 (dd, J = 8.8, 2.4, 1 H, B), 7.67 (dd, J = 8.9, 4.8, 1 H, B), 7.40 (dd, J = 8.6, 2.3, 1 H, A), 7.28– 7.09 (m, 1 H, A + 1 H, B), 6.55 (s, br, 1 H, A), 6.52 (s, br, 1 H, B), 2.50 (s, 3 H, A + 3 H, B) (Note: The A/B isomer assignments are based on ¹H NMR peak integration data: A refers to the major isomer and B refers to the minor isomer); ¹³C NMR (75 MHz, $CDCl_3$): δ 160.9 (d, J = 243), 159.8 (d, J = 243), 159.4, 159.3, 149.3, 148.9, 143.3 (d, J = 12.5), 138.3 (d, J = 1.4), 131.1 (d, J = 13.9), 127.6 (d, J = 1.4), 119.2 (d, *J* = 9.7), 116.8 (d, *J* = 9.7), 115.5, 115.3, 114.1 (d, *J* = 25.0), 112.2 (d, *J* = 25.0), 104.8 (d, *J* = 25.0), 103.3 (d, *J* = 29.8), 22.9, 22.8; ¹⁹F NMR (471 MHz, CDCl₃): δ –108.5 (s), –109.7 (s); GC-MS [A + B]: $m/z 234 (M^+, 100), 206 (32), 191 (3), 168 (32), 162 (8), 147 (5),$ 136 (4), 108 (16), 95 (5); Anal. calcd for C₁₁H₇FN₂OS (234.25): C, 56.40; H, 3.01; F 8.11; N, 11.96; S, 13.69; found C, 56.29; H, 3.02; N 11.99; S, 13.65.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01028.

Copies of ¹H NMR, ¹³C NMR, and ¹⁹F NMR spectra for all products (PDF)

AUTHOR INFORMATION

Corresponding Authors

*E-mail: lucia.veltri@unical.it.

*E-mail: bartolo.gabriele@unical.it.

Notes

The authors declare no competing financial interest.

REFERENCES

(1) (a) Garaliene, V.; Labanauskas, L.; Brukštus, A. Arzneim. Forsch.
2006, 56, 282–287. (b) Brukshtus, A. B.; Garalene, V. N.; Sirvidite, A. R.-R.; Daukshas, V. K. Pharm. Chem. J. 1994, 28, 392–395.
(c) Brukshtus, A. B.; Garalene, V. N.; Sirvidite, A. R.-R.; Daukshas, V. K. Pharm. Chem. J. 1993, 26, 851–854.

(2) Crossley, R.; 4,873,237, 1989.

(3) See, for examples: (a) Khalil, A. K. Phosphorus, Sulfur Silicon Relat. Elem. 2007, 182, 815–823. (b) Britsun, V. N.; Lozinskii, M. O. Chem. Heterocycl. Compd. 2003, 39, 960–964. (c) Bell, S. C.; Wei, P. H. L. J. Med. Chem. 1976, 19, 524–530.

(4) Modern Carbonylation Methods; Kollár, L., Ed.; Wiley: Weinheim, Germany, 2008.

(5) For selected recent reviews, see: (a) Gabriele, B.; Salerno, G. Cyclocarbonylation. In *Handbook of Organopalladium Chemistry for Organic Synthesis*; Negishi, E., Ed.; Wiley-Interscience: New York, 2002; Vol. 2, pp 2623–2641. (b) Wu, X.-F.; Neumann, H.; Beller, M. *Chem. Rev.* 2013, 113, 1–35. (c) Gabriele, B.; Mancuso, R.; Salerno, G. *Eur. J. Org. Chem.* 2012, 2012, 6825–6839.

The Journal of Organic Chemistry

(6) For some very recent examples, see: (a) Mancuso, R.; Raut, D. S.; Marino, N.; De Luca, G.; Giordano, C.; Catalano, S.; Barone, I.; Andò, S.; Gabriele, B. *Chem. - Eur. J.* **2016**, *22*, 3053–3064. (b) Yu, H.; Zhang, G.; Huang, H. *Angew. Chem., Int. Ed.* **2015**, *54*, 10912–10916. (c) Veltri, L.; Mancuso, R.; Altomare, A.; Gabriele, B. *ChemCatChem* **2015**, *7*, 2206–2213.

(7) Substrates 1 were easily prepared by propargylation of 1,3dihydrobenzimidazole-2-thiones, as described in the Experimental Section.

(8) A blank experiment, carried out on 1a under the same conditions as those of entry 1 (Table 1) but in the absence of carbon monoxide, resulted in partial substrate decomposition. On the other hand, when product 2a was heated under the same conditions as those of entry 1 (Table 1), it could be recovered practically unreacted. These results show that 2a was stable under the reaction conditions and that the formation of chromatographically immobile materials observed in the carbonylation reaction of 1a reported in entry 1 (Table 1) must be due to partial substrate decomposition rather than product instability.

(9) (a) Gabriele, B.; Salerno, G. PdI₂. In *e-EROS (Electronic Encyclopedia of Reagents for Organic Synthesis)*; Crich, D., Ed.; Wiley-Interscience: New York, 2006. (b) Gabriele, B.; Salerno, G.; Costa, M. *Top. Organomet. Chem.* 2006, 18, 239–272. (c) Gabriele, B.; Salerno, G.; Costa, M.; Chiusoli, G. P. *Curr. Org. Chem.* 2004, 8, 919–946. (d) Gabriele, B.; Salerno, G.; Costa, M. *Synlett* 2004, 2004, 2468–2483. (e) Gabriele, B.; Salerno, G.; Costa, M.; Chiusoli, G. P. J. Organomet. Chem. 2003, 687, 219–228.

(10) For an interesting review on iodide effects in transition metalcatalyzed reactions, including carbonylations, see: Maitlis, P. M.; Haynes, A.; James, B. R.; Catellani, M.; Chiusoli, G. P. *Dalton Trans.* **2004**, 3409–3419.

(11) See, for example: Yin, X.; Moss, J. R. Coord. Chem. Rev. 1999, 181, 27–59 and references therein..

(12) Procedure adapted from: (a) Zhivotova, T. S.; Gazaliev, A. M.; Fazylov, S. D.; Aitpaeva, Z. K.; Turdybekov, D. M. Russ. J. Org. Chem. **2006**, 42, 448–450. See also: (b) Veltri, L.; Grasso, G.; Rizzi, R.; Mancuso, R.; Gabriele, B. Asian J. Org. Chem. **2016**, 5, 560–567.

(13) Perrin, L.; Hudhomme, P. Eur. J. Org. Chem. 2011, 28, 5427-5440.

(14) Procedure adapted from: Barbosa, F. C. G.; de Oliveira, R. N. J. Braz. Chem. Soc. 2011, 22, 592–597 See also reference 12b.

(15) Yaroshenko, T. I.; Nakhmanovich, A. S.; Larina, L. I.; Elokhina, V. N.; Amosova, S. V. Chem. Heterocycl. Compd. 2008, 44, 1129–1134.